Media Newsroom of

Enterin Inc.

3624 Market St Suite 517
Philadelphia, PA 19104
Website: http://www.enterininc.com

Enterin Inc. is an early stage CNS pharmaceutical company located in Philadelphia, specializing in the treatment of neurodegenerative diseases caused by a dysfunctional gut-brain axis.

Enterin to Conduct a Randomized Phase 1/2a Study in Hospitalized Patients With COVID-19

Enterin to Conduct a Randomized Phase 1/2a Study in Hospitalized Patients With COVID-19

Enterin, Inc., a clinical-stage company focused on neurodegenerative diseases, announced today that it has received feedback from the FDA laying out the path for a Phase 1/2a study in hospitalized patients with COVID-19 infection. The study will involve 10 U.S.…

ENT-01, Currently in Human Trials, Rejuvenates Aging Nervous System

ENT-01, Currently in Human Trials, Rejuvenates Aging Nervous System

​Enterin Inc., a privately held, CNS-focused pharmaceutical company based in Philadelphia and developing novel compounds to treat neurodegenerative diseases, announces the publication of an article entitled “Colonic motility and jejunal vagal afferent firing rates are decreased in aged adult male mice and…

Enterin's RASMET Study Published

Enterin's RASMET Study Published

​​​Enterin Inc., a privately held, CNS-focused pharmaceutical company based in Philadelphia developing novel compounds to treat neurodegenerative diseases, announces the publication of its Phase 2a RASMET study. The article entitled “Targeting neurons in the gastrointestinal tract to treat Parkinson’s Disease” was…

Enterin's DEMET Study Enrolls First Patient With Parkinson's Disease Dementia (PDD)

Enterin's DEMET Study Enrolls First Patient With Parkinson's Disease Dementia (PDD)

​Enterin Inc., a CNS pharmaceutical company based in Philadelphia and developing novel compounds to treat Parkinson’s disease (PD), has enrolled the first patient in the DEMET study. The study is an open label multi-center study involving patients with PDD and taking…

Enterin's Phase 2a RASMET Study in Patients With Parkinson's Disease Completes Enrollment

Enterin's Phase 2a RASMET Study in Patients With Parkinson's Disease Completes Enrollment

Enterin Inc., a CNS pharmaceutical company based in Philadelphia and developing novel compounds to treat Parkinson’s disease (PD), autism and schizophrenia, has completed enrollment of a two-stage Phase 2a study of ENT-01 in patients with PD. The study was conducted at…

Enterin Inc. Raises $12.7 Million in Series A Financing

Enterin Inc. Raises $12.7 Million in Series A Financing

​​​​Enterin Inc., a Philadelphia-based biotechnology company developing novel compounds to treat Parkinson's disease (PD), today announced the completion of a $12.7 million Series A financing round. The financing included new investors New Ventures III, as well as the participation of…

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or Signup using Email

Already have an account ? Login

Reset Password

Already have an account ? Login